Bridgebio Oncology Therapeutics, Inc. (BBOT)
2.04
-0.13
(-5.99%)
USD |
NASDAQ |
Nov 06, 16:00
2.08
+0.04
(+1.96%)
After-Hours: 20:00
Bridgebio Oncology Therapeutics Research and Development Expense (Annual) : 121.20M for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | 121.20M |
| Date | Value |
|---|---|
| December 31, 2024 | 73.11M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| Korsana Biosciences, Inc. | 0.959M |
| IRulya Therapeutics, Inc. | 35.38M |
| PepGen Inc. | 69.65M |
| Q32 Bio, Inc. | 19.16M |
| Arrowhead Pharmaceuticals, Inc. | 585.26M |